Predicting the commercial potential of a drug is difficult and time consuming if you don’t have the data to support your assumptions. When these data are spread among multiple sources, your task can be time consuming at best, and impossible at worst.
Thomson Pharma Partnering Forecast gives you the most accurate available method of assessing the sales potential of new drugs by integrating and summarizing multiple perspectives on drugs that will compete with yours.
For each therapeutic franchise, Thomson Pharma Partnering Forecast enables you to compare the most significant candidates in the development pipeline and the key drugs that have reached the market. It provides a consensus of analyst forecasts for pipeline and marketed drugs, and downloadable, patient-based revenue models for drugs in over 100 indications, providing transparent assumptions on incidence and prevalence, eligible numbers of patients, estimated timing of approval, pricing, and market share within the indication.
You can search by drug, franchise or company. More than 3,000 drugs are currently monitored, with more coming into the database every day.
Thomson Pharma Partnering Forecast gives you the data you need to quickly develop forecasts for your pipeline or marketed drug.
With Thomson Pharma Partnering Forecast, you can:
- Compare the drug you are evaluating to those it will compete with.
- Evaluate drug summaries, partnering and development history, upcoming events likely to affect approval, and numerical ratings on likelihood of approval.
- Review both consensus analyst market forecasts and transparent, patient-based forecasts for drugs that will compete with yours.
- Download patient-based forecasts and factor in your assumptions.
Why choose Thomson Pharma Partnering Forecast?
- Each drug tracked in Thomson Pharma Partnering Forecast includes a summary of the drug, the company(ies) developing it, the indications and mechanism of action, and links to similar drugs.
- Analysts focused exclusively on the pharmaceutical industry give you a head start on quantifying its likelihood of approval. They appraise the scientific, clinical and regulatory catalysts that will affect its progress, and assign and regularly update a likelihood-of-approval score.
- It provides a consensus of analyst forecasts for the most strategic drugs in each therapeutic franchise, and downloadable, patient-based revenue models for drugs in over 100 indications, providing transparent assumptions on incidence and prevalence, eligible numbers of patients, estimated timing of approval, pricing, and market share within the indication.
- Those who also subscribe to Thomson Pharma Partnering Pipeline can access the full drug report, giving you the background information you need to accurately assess the competitive landscape surrounding it.
Contact Us
Americas
Tel: +1 800.336.4474
Tel: +1 215.386.0100
Fax: +1 215.386.2911
Europe, Middle East & Africa
Tel: +44 20.7433.4000
Japan
Tel: +81 3.5218.6500
Tel: 0800 888.8855 (free dial from Japan only)
Fax: +81 3.5218.7840
Asia Pacific
Tel: +65 6411.6888
Fax: +65 6223.2634